Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could slow MS relapses and disability

NCT ID NCT05156281

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether the oral drug remibrutinib works better than teriflunomide at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 1,000 adults aged 18–55 with active MS are taking part. The study is double-blind, meaning neither participants nor doctors know who gets which drug, and will be followed by an open-label extension where everyone can receive remibrutinib.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remibrutinib (a tablet taken by mouth)
What this could lead to
If successful, remibrutinib could offer a new oral treatment option for relapsing multiple sclerosis, potentially reducing relapses and slowing disability.
What could go wrong
This is a Phase 3 trial, but results are not yet available. It compares against an existing drug, so the benefit may be modest. Side effects are possible, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,007 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 to 55 years of age * Diagnosis of RMS according to the 2017 McDonald diagnostic criteria * At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months. * EDSS score of 0 to 5.5 (inclusive) * Neurologically stable within 1 month Exclusion Criteria: * Diagnosis of primary progressive multiple sclerosis (PPMS) * Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening * History of clinically significant CNS disease other than MS * Ongoing substance abuse (drug or alcohol) * History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer), * Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML * suicidal ideation or behavior * Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence * Participants who have had a splenectomy * Active clinically significant systemic bacterial, viral, parasitic or fungal infections * Positive results for syphilis or tuberculosis testing * Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids * Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder. * Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody * History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease. * History of severe renal disease or creatinine level * Participants at risk of developing or having reactivation of hepatitis * Hematology parameters at screening: * Hemoglobin: \< 10 g/dl (\<100g/L) * Platelets: \< 100000/mm3 (\<100 x 109/L) * Absolute lymphocyte count \< 800/mm3 (\<0.8 x 109/L) * White blood cells: \<3 000/mm3 (\<3.0 x 109/L) * Neutrophils: \< 1 500/mm3 (\<1.5 x 109/L) * B-cell count \< 50% lower limit of normal (LLN) or total IgG \& total IgM \< LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening) * History or current diagnosis of significant ECG abnormalities * Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit * Use of other investigational drugs * Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders, * History of gastrointestinal bleeding * Major surgery within 8 weeks prior to screening * History of hypersensitivity to any of the study drugs or excipients * Pregnant or nursing (lactating) female participants, prior to randomization * Women of childbearing potential not using highly effective contraception * Sexually active males not agreeing to use condom * Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study * Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization Inclusion to Extension part: • Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP) Other inclusion and exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsing multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Charcot-Marie-Tooth disease type 1F Recurrence relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsing multiple sclerosis

Contacts and locations

Locations

  • Advent Health Orlando

    Orlando, Florida, 32803, United States

  • Aqualane Clinical Research

    Naples, Florida, 34105, United States

  • Ascension St Francis Center

    Milwaukee, Wisconsin, 53215, United States

  • Baptist Physicians Lexington

    Nicholasville, Kentucky, 40356, United States

  • Baylor Scott and White

    Temple, Texas, 76508, United States

  • Brain and Spine Institute

    Port Orange, Florida, 32127, United States

  • CU Anschutz Med Campus

    Aurora, Colorado, 80045, United States

  • Caribbean Center for Clinical Research Inc

    Guaynabo, 00968, Puerto Rico

  • Clinre Comprehensive Neurology

    Frederick, Maryland, 21702, United States

  • Colorado Neurological Research PC

    Denver, Colorado, 80210, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Ctr for Neurology and Spine

    Phoenix, Arizona, 85018, United States

  • Elligo Health Research

    Crab Orchard, West Virginia, 25827, United States

  • Emerald Coast Neurology

    Pensacola, Florida, 32514, United States

  • Gables Neurology

    Miami, Florida, 33133, United States

  • Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • Georgetown University Hospital Research

    Washington D.C., District of Columbia, 20007, United States

  • Humanity Clinical Research

    Pembroke Pines, Florida, 33024, United States

  • Kansas City VA Medical Center

    Kansas City, Missouri, 64128, United States

  • Lone Star Neurology

    Frisco, Texas, 75035, United States

  • Lonestar Neurology of San Antonio

    San Antonio, Texas, 78258, United States

  • Med Research Inc

    El Paso, Texas, 79935, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Healthcare System

    Hollywood, Florida, 33021, United States

  • Methodist Neuroscience Institute

    Merrillville, Indiana, 46410, United States

  • Metrolina Neurological Associates PA

    Old Point Station, South Carolina, 29707, United States

  • Neurology Associates PA

    Maitland, Florida, 32751, United States

  • Neurology Consultants Of Dallas PA

    Dallas, Texas, 75231, United States

  • Neurology Diagnostics Inc

    Dayton, Ohio, 45408, United States

  • New England Institute for Clinical Research

    Stamford, Connecticut, 06905, United States

  • Nova Clinical Research LLC

    Bradenton, Florida, 34209, United States

  • Novartis Investigative Site

    Bombal, Mendoza Province, M5500DXO, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000BZL, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, S2000DSW, Argentina

  • Novartis Investigative Site

    San Miguel de, Tucumán Province, T4000, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1012AAR, Argentina

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Córdoba, X5004CDT, Argentina

  • Novartis Investigative Site

    Vitória, Espírito Santo, 29055-450, Brazil

  • Novartis Investigative Site

    Brasília, Federal District, 70200-730, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, 81210-310, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90430-001, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90560-032, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90620-130, Brazil

  • Novartis Investigative Site

    Joinville, Santa Catarina, 89202-165, Brazil

  • Novartis Investigative Site

    São Paulo, 01240-020, Brazil

  • Novartis Investigative Site

    Plovdiv, 4002, Bulgaria

  • Novartis Investigative Site

    Sofia, 1309, Bulgaria

  • Novartis Investigative Site

    Sofia, 1407, Bulgaria

  • Novartis Investigative Site

    Sofia, 1431, Bulgaria

  • Novartis Investigative Site

    Edmonton, Alberta, T6G 2B7, Canada

  • Novartis Investigative Site

    Burnaby, British Columbia, V5G 2X6, Canada

  • Novartis Investigative Site

    Halifax, Nova Scotia, B3H 4K4, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Novartis Investigative Site

    Lévis, Quebec, G6W 0M5, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H4A 3T2, Canada

  • Novartis Investigative Site

    Québec, Quebec, G1J 1Z4, Canada

  • Novartis Investigative Site

    Saint-Jérôme, Quebec, J7Z 5T3, Canada

  • Novartis Investigative Site

    Wuhan, Hubei, 430030, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430060, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210029, China

  • Novartis Investigative Site

    Yinchuan, Ningxia, 750004, China

  • Novartis Investigative Site

    Taiyuan, Shanxi, 030001, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310006, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310016, China

  • Novartis Investigative Site

    Wenzhou, Zhejiang, 325000, China

  • Novartis Investigative Site

    Beijing, 100034, China

  • Novartis Investigative Site

    Shanghai, 200025, China

  • Novartis Investigative Site

    Shanghai, 200040, China

  • Novartis Investigative Site

    Zagreb, Croatia, 10000, Croatia

  • Novartis Investigative Site

    Split, HRV, 21000, Croatia

  • Novartis Investigative Site

    Varaždin, HRV, 42000, Croatia

  • Novartis Investigative Site

    Vukovar, Vukovar, 32000, Croatia

  • Novartis Investigative Site

    Zagreb, 10000, Croatia

  • Novartis Investigative Site

    Brno, 602 00, Czechia

  • Novartis Investigative Site

    Hradec Králové, 500 05, Czechia

  • Novartis Investigative Site

    Teplice, 415 29, Czechia

  • Novartis Investigative Site

    Tallinn, 11315, Estonia

  • Novartis Investigative Site

    Tartu, 50406, Estonia

  • Novartis Investigative Site

    Limoges, Haute Vienne, 87000, France

  • Novartis Investigative Site

    Toulon, Val De Marne, 83800, France

  • Novartis Investigative Site

    Caen, 14033, France

  • Novartis Investigative Site

    Clermont-Ferrand, 63003, France

  • Novartis Investigative Site

    Dijon, 21000, France

  • Novartis Investigative Site

    Gonesse, 95500, France

  • Novartis Investigative Site

    Grenoble, 38043, France

  • Novartis Investigative Site

    Lille, 59000, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Nice, 06001, France

  • Novartis Investigative Site

    Nîmes, 30029, France

  • Novartis Investigative Site

    Poissy, 78303, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Hamburg, 22179, Germany

  • Novartis Investigative Site

    Athens, 115 28, Greece

  • Novartis Investigative Site

    Athens, 11526, Greece

  • Novartis Investigative Site

    Chaïdári, 124 62, Greece

  • Novartis Investigative Site

    Ioannina, 455 00, Greece

  • Novartis Investigative Site

    Larissa, 411 10, Greece

  • Novartis Investigative Site

    Thessaloniki, 53246, Greece

  • Novartis Investigative Site

    Thessaloniki, 54636, Greece

  • Novartis Investigative Site

    Kochi, Kerala, 682025, India

  • Novartis Investigative Site

    Pune, Maharashtra, 411013, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110060, India

  • Novartis Investigative Site

    Amritsar, Punjab, 143006, India

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226007, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700017, India

  • Novartis Investigative Site

    Brindisi, BR, 72100, Italy

  • Novartis Investigative Site

    Foggia, FG, 71122, Italy

  • Novartis Investigative Site

    Pozzilli, IS, 86077, Italy

  • Novartis Investigative Site

    Messina, ME, 98124, Italy

  • Novartis Investigative Site

    Modena, MO, 41126, Italy

  • Novartis Investigative Site

    Pavia, PV, 27100, Italy

  • Novartis Investigative Site

    Orbassano, TO, 10043, Italy

  • Novartis Investigative Site

    Naples, 80138, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    Chiba, Chiba, 2608677, Japan

  • Novartis Investigative Site

    Ichihara, Chiba, 2990111, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 810-0022, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0630005, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, 650-0017, Japan

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, 6638501, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, 259-1193, Japan

  • Novartis Investigative Site

    Sagamihara, Kanagawa, 252-0375, Japan

  • Novartis Investigative Site

    Kyoto, Kyoto, 616-8255, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9838512, Japan

  • Novartis Investigative Site

    Kashihara, Nara, 6348522, Japan

  • Novartis Investigative Site

    Niigata, Niigata, 951-8520, Japan

  • Novartis Investigative Site

    Moriguchi, Osaka, 570-8507, Japan

  • Novartis Investigative Site

    Suita, Osaka, 565-0871, Japan

  • Novartis Investigative Site

    Higashi-Matsuyama, Saitama, 355-0005, Japan

  • Novartis Investigative Site

    Itabashi-ku, Tokyo, 1738610, Japan

  • Novartis Investigative Site

    Kodaira, Tokyo, 187-8551, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 1628666, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1608582, Japan

  • Novartis Investigative Site

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    Chihuahua City, Chihuahua, 31203, Mexico

  • Novartis Investigative Site

    Mexico City, Mexico City, 06700, Mexico

  • Novartis Investigative Site

    Mexico City, 14050, Mexico

  • Novartis Investigative Site

    Querétaro, 76070, Mexico

  • Novartis Investigative Site

    Plewiska, Poznan, 62-064, Poland

  • Novartis Investigative Site

    Bialystok, 15-704, Poland

  • Novartis Investigative Site

    Glogow Wielkopolski, 36-060, Poland

  • Novartis Investigative Site

    Katowice, 40-081, Poland

  • Novartis Investigative Site

    Katowice, 40-571, Poland

  • Novartis Investigative Site

    Katowice, 40-686, Poland

  • Novartis Investigative Site

    Katowice, 40-689, Poland

  • Novartis Investigative Site

    Lublin, 20-701, Poland

  • Novartis Investigative Site

    Wroclaw, 51-685, Poland

  • Novartis Investigative Site

    Zabrze, 41-800, Poland

  • Novartis Investigative Site

    Braga, 4710243, Portugal

  • Novartis Investigative Site

    Coimbra, 3004-561, Portugal

  • Novartis Investigative Site

    Leiria, 2410-197, Portugal

  • Novartis Investigative Site

    Lisbon, 1169-050, Portugal

  • Novartis Investigative Site

    Lisbon, 1649-035, Portugal

  • Novartis Investigative Site

    Matosinhos Municipality, 4454-513, Portugal

  • Novartis Investigative Site

    Santa Maria da Feira, 4520-211, Portugal

  • Novartis Investigative Site

    Brasov, ROM, 500123, Romania

  • Novartis Investigative Site

    Constanța, ROM, 900123, Romania

  • Novartis Investigative Site

    Campulung Muscel, 115100, Romania

  • Novartis Investigative Site

    Constanța, 900591, Romania

  • Novartis Investigative Site

    Banská Bystrica, 974 04, Slovakia

  • Novartis Investigative Site

    Banská Bystrica, 975 17, Slovakia

  • Novartis Investigative Site

    Bratislava, 833 05, Slovakia

  • Novartis Investigative Site

    Maribor, Slovenia, 2000, Slovenia

  • Novartis Investigative Site

    Celje, 3000, Slovenia

  • Novartis Investigative Site

    Ljubljana, 1000, Slovenia

  • Novartis Investigative Site

    Bloemfontein, Free State, 9301, South Africa

  • Novartis Investigative Site

    Pretoria, 0041, South Africa

  • Novartis Investigative Site

    Rosebank, 2196, South Africa

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    Vitoria-Gasteiz, Araba, 01009, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Albacete, Castille-La Mancha, 02006, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, 08003, Spain

  • Novartis Investigative Site

    Logroño, La Rioja, 26006, Spain

  • Novartis Investigative Site

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Novartis Investigative Site

    Torrejón de Ardoz, Madrid, 28850, Spain

  • Novartis Investigative Site

    Gijón, Principality of Asturias, 33394, Spain

  • Novartis Investigative Site

    Valencia, Valencia, 46017, Spain

  • Novartis Investigative Site

    Lleida, 25198, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Málaga, 29016, Spain

  • Novartis Investigative Site

    Seville, 41009, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Stockholm, 102 35, Sweden

  • Novartis Investigative Site

    Samsun, Atakum, 55200, Turkey (Türkiye)

  • Novartis Investigative Site

    Izmir, Balcova, 35340, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Fatih, 34093, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Fatih, 34098, Turkey (Türkiye)

  • Novartis Investigative Site

    Izmir, Karabaglar, 35150, Turkey (Türkiye)

  • Novartis Investigative Site

    Köseköy, Kocaeli, 41380, Turkey (Türkiye)

  • Novartis Investigative Site

    Kayseri, Melikgazi, 38039, Turkey (Türkiye)

  • Novartis Investigative Site

    Bursa, Nilufer, 16140, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Pendik, 34899, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Sancaktepe, 34785, Turkey (Türkiye)

  • Novartis Investigative Site

    Konya, 42130, Turkey (Türkiye)

  • Novartis Investigative Site

    Inverness, Invernesshire, IV2 3RE, United Kingdom

  • Novartis Investigative Site

    Canterbury, Kent, CT1 3NG, United Kingdom

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121, United States

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania, 17033, United States

  • Piedmont HealthCare

    Charlotte, North Carolina, 28210, United States

  • Premier Neurology

    Greenville, South Carolina, 29605, United States

  • Regina Berkovich MD PhD Inc

    West Hollywood, California, 90048, United States

  • Sibyl Wray MD Neurology PC

    Knoxville, Tennessee, 37922, United States

  • South Shore Neurologic Associates

    Patchogue, New York, 11772, United States

  • Texas Institute for Neurological Disorders

    Sherman, Texas, 75092, United States

  • The Boster Ctr for MS

    Columbus, Ohio, 43235, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

  • UM Department Of Neurology

    Miami, Florida, 33136, United States

  • UT Health MARC Medical Arts and Research Center

    San Antonio, Texas, 78229, United States

  • University Of NC At Chapel Hill

    Chapel Hill, North Carolina, 27599 9500, United States

  • University of Florida

    Gainesville, Florida, 32610, United States

  • University of Kansas Hospital

    Kansas City, Kansas, 66160, United States

  • University of Washington MS Clinic

    Seattle, Washington, 98133, United States

  • VA Greater LA Healthcare System

    Los Angeles, California, 90073, United States

  • Vero Beach Neurology

    Vero Beach, Florida, 32960, United States

  • Virginia Mason Medical Centre

    Seattle, Washington, 98101, United States

  • Vladimir Royter MD APMC

    Hanford, California, 93230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.